Lignocellulosic biomass is a flexible renewable useful resource for fuels, buildings, crafts, and biomaterials. Strategies of molecularly designing lignocellulose for industrial software has been developed by the discoveries of novel genes after the screenings of varied mutants and remodeled traces of Arabidopsis whose cell partitions might be modified in the inflorescence stem, a mannequin woody tissue. The mechanical properties are used as a quantitative index for the chemorehological conduct of the genetically modified cell wall in the tissue.
This parameter could be measured with tensile or bending checks of tissue explants, the vibration evaluation of tissue conduct or utilizing atomic power microscopy to probe the tissue floor. Here, we describe in element the process to find out the stiffness of methanol-fixed, rehydrated and pronase-treated inflorescence explants with a tensile testing machine primarily based on classical strategies for the dedication of cell wall extensibility.
Extracellular matrix (ECM)-based tissue engineering scaffolds have a necessary position in selling tissue regeneration. Nerve tissue engineering goals at facilitating the restore of everlasting injury to the peripheral and central nervous methods, that are tough to heal. For this function, a range of biomaterials are being developed consisting of quite a few artificial and/or pure polymers to offer axonal reinnervation and to direct the development of axons. Here, we current a novel protocol that permits to manufacture a three-d (3D) decellularized scaffold derived from the bovine spinal twine (BSC) ECM (3D-dCBS) for neural tissue engineering purposes.
In this protocol, a viscous ECM-derived gel from BSC is ready, molded, and chemically crosslinked with EDC/NHS (3D-CBS) earlier than decellularization course of. Decellularization of 3D-CBS is carried out with 1% SDS to realize 3D-dCBS. As in contrast with different out there strategies, our protocol is a novel decellularization technique that preserves a extra important half of the ECM. We imagine that the talked about protocol has the potential to supply a bioengineered scaffold from spinal twine tissue with desired geometry for regenerative drugs purposes associated to neural tissue engineering.
The Fabrication of Poly( Σ-caprolactone)-Poly(ethylene oxide) Sandwich Type Nanofibers Containing Sericin-Capped Silver Nanoparticles as an Antibacterial Wound Dressing
In this examine, antibacterial, artificial poly(Σ-caprolactone)-poly(ethylene oxide) (PCL-PEO) multilayer nanofibers had been produced by an electrospinning technique. The materials was synthesized in Three layers. The upper-lower protecting layers had been produced by PCL nanofibers and the intermediate layer was produced from PEO nanofiber containing sericin-capped silver nanoparticles (S-AgNPs). The electrospinning circumstances in which nano-sized, clean, bead-free fibers had been obtained was decided to be an utilized voltage of 20 kV, a circulate price of 8 μL/min and a distance between the collector and the needle tip of 22 cm for the PCL layer (dissolved at a 12% g/mL focus in a chloroform:methanol (3:2) solvent combination) layer.
For the S-AgNPs doped PEO layer (dissolved at a 3.5% g/mL focus in water), the corresponding circumstances had been decided to be 20 kV, 15 μL/min and 20 cm.To characterize the three-layer materials that consisted of PCL and S-AgNPs doped PEO layers, FTIR and SEM analyses had been carried out, and the water retention capability, in situ degradability and antibacterial exercise of the materials was investigated.
According to SEM evaluation, the fibers obtained had been discovered to be nano-sized, clean and bead-free and the common measurement of the nanofibers forming the PCL layer was 687 nm whereas the common measurement of the fibers forming the PEO layer was 98 nm. Antibacterial exercise checks had been carried out utilizing gram-positive (Staphylococcus aureus ATCC 6538) and gram-negative (Escherichia coli ATCC 25922) micro organism and the ensuing biomaterial was discovered to have antimicrobial impact on each gram-negative and gram-positive micro organism. It was decided that the 3-layer materials obtained in this examine can be utilized as a wound dressing.
Peptide-Chitosan Engineered Scaffolds for Biomedical Applications
Peptides are signaling epitopes that management many important organic occasions. Increased specificity, artificial feasibility with concomitant lack of toxicity, and immunogenicity make this rising class of biomolecules appropriate for totally different purposes together with therapeutics, diagnostics, and biomedical engineering. Further, chitosan, a naturally occurring linear polymer composed of d-glucosamine and N-acetyl-d-glucosamine items, possesses anti-microbial, muco-adhesive, and hemostatic properties together with wonderful biocompatibility.
As a end result, chitosan finds software in drug/gene supply, tissue engineering, and bioimaging. Despite these purposes, chitosan demonstrates restricted cell adhesion and lacks biosignaling. Therefore, peptide-chitosan hybrids have emerged as a brand new class of biomaterial with improved biosignaling properties and cell adhesion properties. As a end result, current research embody elevated software of peptide-chitosan hybrids as composites or conjugates in drug supply, cell remedy, and tissue engineering and as anti-microbial materials. This evaluate discusses the current investigations involving chitosan-peptide supplies and uncovers varied facets of these attention-grabbing hybrid supplies for biomedical purposes.
 scFv-MAP ADC) Anti-TNFRSF8 (clone Ki4) scFv-MAP ADC |
|
ADC-W-354 |
Creative Biolabs |
1mg |
Ask for price |
|
Description: This ADC product is comprised of an anti-TNFRSF8 monoclonal antibody (clone Ki4) conjugated via a linker to a MAP |
 Anti-Tetanus Toxoid scFv IgG) Recombinant (E.Coli) Anti-Tetanus Toxoid scFv IgG |
|
RP-343 |
Alpha Diagnostics |
10 ug |
EUR 286 |
 scFv-Fc-Sec ADC) Anti-ROR1 (clone R11) scFv-Fc-Sec ADC |
|
ADC-W-434 |
Creative Biolabs |
1mg |
Ask for price |
|
Description: This ADC product is comprised of an anti-ROR1 scFv-Fc (clone R11) conjugated via a engineered selenocysteine (Sec) residue linker to a drug |
) Control siRNA Vector (pGB-control) |
|
9500C-20 |
Biovision |
|
EUR 338 |
) Recombinant Anti-BCMA x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-020-100ug |
Creative Biolabs |
100μg |
EUR 3560 |
|
Description: A bispecific antibody that is expressed as an anti-BCMA scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Multiple myeloma (MM) therapy. |
|
Recombinant Anti-BCMA x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-020-50ug |
Creative Biolabs |
50μg |
EUR 2039 |
|
Description: A bispecific antibody that is expressed as an anti-BCMA scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Multiple myeloma (MM) therapy. |
) Recombinant Anti-CD123 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-030-100ug |
Creative Biolabs |
100μg |
EUR 3560 |
|
Description: A bispecific antibody that is expressed as an anti-CD123 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Acute myelogenous leukemia (AML); Chronic myelogenous leukemia (CML); Plasmacytoid leukemia therapy. |
|
Recombinant Anti-CD123 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-030-50ug |
Creative Biolabs |
50μg |
EUR 2039 |
|
Description: A bispecific antibody that is expressed as an anti-CD123 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Acute myelogenous leukemia (AML); Chronic myelogenous leukemia (CML); Plasmacytoid leukemia therapy. |
) Recombinant Anti-CD19 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-041-100ug |
Creative Biolabs |
100μg |
EUR 3794 |
|
Description: A bispecific antibody that is expressed as an anti-CD19 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy. |
|
Recombinant Anti-CD19 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-041-50ug |
Creative Biolabs |
50μg |
EUR 2156 |
|
Description: A bispecific antibody that is expressed as an anti-CD19 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy. |
) Recombinant Anti-CD2 x Anti-EGFR Bispecific Antibody (Tandem scFv) |
|
BSFV-046-100ug |
Creative Biolabs |
100μg |
EUR 3560 |
|
Description: A bispecific antibody that is expressed as an anti-CD2 scFv fused with an anti-EGFR scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy. |
|
Recombinant Anti-CD2 x Anti-EGFR Bispecific Antibody (Tandem scFv) |
|
BSFV-046-50ug |
Creative Biolabs |
50μg |
EUR 2039 |
|
Description: A bispecific antibody that is expressed as an anti-CD2 scFv fused with an anti-EGFR scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy. |
) Recombinant Anti-CD33 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-066-100ug |
Creative Biolabs |
100μg |
EUR 3560 |
|
Description: A bispecific antibody that is expressed as an anti-CD33 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Acute myeloid leukemia (AML); Ulcerative Colitis (UC); Myelodysplastic syndromes (MDS); Gastric cancer therapy. |
|
Recombinant Anti-CD33 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-066-50ug |
Creative Biolabs |
50μg |
EUR 2039 |
|
Description: A bispecific antibody that is expressed as an anti-CD33 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Acute myeloid leukemia (AML); Ulcerative Colitis (UC); Myelodysplastic syndromes (MDS); Gastric cancer therapy. |
) Recombinant Anti-CD3 x Anti-CEA Bispecific Antibody (Tandem scFv) |
|
BSFV-072-100ug |
Creative Biolabs |
100μg |
EUR 3560 |
|
Description: A bispecific antibody that is expressed as an anti-CD3 scFv fused with an anti-CEA scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Colorectal cancer (CRC); Breast cancer; Lung cancer; Gastric cancer therapy. |
|
Recombinant Anti-CD3 x Anti-CEA Bispecific Antibody (Tandem scFv) |
|
BSFV-072-50ug |
Creative Biolabs |
50μg |
EUR 2039 |
|
Description: A bispecific antibody that is expressed as an anti-CD3 scFv fused with an anti-CEA scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Colorectal cancer (CRC); Breast cancer; Lung cancer; Gastric cancer therapy. |
) Recombinant Anti-EGFR x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-077-100ug |
Creative Biolabs |
100μg |
EUR 3560 |
|
Description: A bispecific antibody that is expressed as an anti-EGFR scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy. |
|
Recombinant Anti-EGFR x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-077-50ug |
Creative Biolabs |
50μg |
EUR 2039 |
|
Description: A bispecific antibody that is expressed as an anti-EGFR scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy. |
) Recombinant Anti-EPCAM x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-079-100ug |
Creative Biolabs |
100μg |
EUR 3560 |
|
Description: A bispecific antibody that is expressed as an anti-EPCAM scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Solid tumors therapy. |
|
Recombinant Anti-EPCAM x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-079-50ug |
Creative Biolabs |
50μg |
EUR 2039 |
|
Description: A bispecific antibody that is expressed as an anti-EPCAM scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Solid tumors therapy. |
) Recombinant Anti-CD3 x Anti-PSMA Bispecific Antibody (Tandem scFv) |
|
BSFV-102-100ug |
Creative Biolabs |
100μg |
EUR 3560 |
|
Description: A bispecific antibody that is expressed as an anti-CD3 scFv fused with an anti-PSMA scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Prostate cancer therapy. |
|
Recombinant Anti-CD3 x Anti-PSMA Bispecific Antibody (Tandem scFv) |
|
BSFV-102-50ug |
Creative Biolabs |
50μg |
EUR 2039 |
|
Description: A bispecific antibody that is expressed as an anti-CD3 scFv fused with an anti-PSMA scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Prostate cancer therapy. |
) Recombinant Anti-FIXa x Anti-FX Bispecific Antibody (Tandem scFv) |
|
BSFV-162-100ug |
Creative Biolabs |
100μg |
EUR 3794 |
|
Description: A bispecific antibody that is expressed as an anti-FIXa scFv fused with an anti-FX scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can bind and dimerize two factors. It acts as mimetic FXIII. It is designed for the research of Hemophilia A therapy. |
|
Recombinant Anti-FIXa x Anti-FX Bispecific Antibody (Tandem scFv) |
|
BSFV-162-50ug |
Creative Biolabs |
50μg |
EUR 2156 |
|
Description: A bispecific antibody that is expressed as an anti-FIXa scFv fused with an anti-FX scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can bind and dimerize two factors. It acts as mimetic FXIII. It is designed for the research of Hemophilia A therapy. |
) Recombinant Anti-BSA x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-c001-100ug |
Creative Biolabs |
100μg |
EUR 3794 |
|
Description: A bispecific antibody that is expressed as an anti-BSA scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can be used as a negative control to other anti-CD3 BsAbs in the research of tumor therapy. |
|
Recombinant Anti-BSA x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-c001-50ug |
Creative Biolabs |
50μg |
EUR 2156 |
|
Description: A bispecific antibody that is expressed as an anti-BSA scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can be used as a negative control to other anti-CD3 BsAbs in the research of tumor therapy. |
) Recombinant Anti-CTLA4 x Anti-PD1 Bispecific Antibody (IgG-scFv) |
|
IGFV-146 |
Creative Biolabs |
200μg |
Ask for price |
|
Description: A bispecific antibody that is expressed as a LC and an extended HC with scFv moiety linked to the C terminus. It is a symmetric bispecific and tetravalent molecule, 2+2 antigen-binding valency. This BsAb can bind two factors simultaneously and enhance immune response. It is designed for the research of Tumors therapy. |
) Recombinant Anti-IL17 x Anti-TNF Bispecific Antibody (IgG-scFv) |
|
IGFV-175 |
Creative Biolabs |
200μg |
Ask for price |
|
Description: A bispecific antibody that is designed to be expressed as a LC and an extended HC with scFv moiety linked to the C terminus. It is a symmetric bispecific and tetravalent molecule, 2+2 antigen-binding valency. This BsAb can block two proinflammatory cytokines simultaneously. It is designed for the research of Rheumatoid arthritis (RA); Plaque psoriasis therapy. |
 Quality Control |
|
abx098966-1vial |
Abbexa |
1 vial |
EUR 300 |
- Shipped within 5-7 working days.
|
) Recombinant Anti-CD123 x Anti-CD3 Bispecific Antibody (Fab-scFv-Fc) |
|
FABVC-030-100ug |
Creative Biolabs |
100μg |
EUR 3911 |
|
Description: A bispecific antibody that the Fab of anti-CD123 antibody variable domain is fused to the Fc-knob domain with a hinge region and the same as the scFv of anti-CD3 to the Fc-hole domain, or vice versa. This BsAb can retarget T cells to tumor cells. It is designed for the research of Acute myelogenous leukemia (AML); Chronic myelogenous leukemia (CML); Plasmacytoid leukemia therapy. |
|
Recombinant Anti-CD123 x Anti-CD3 Bispecific Antibody (Fab-scFv-Fc) |
|
FABVC-030-50ug |
Creative Biolabs |
50μg |
EUR 2390 |
|
Description: A bispecific antibody that the Fab of anti-CD123 antibody variable domain is fused to the Fc-knob domain with a hinge region and the same as the scFv of anti-CD3 to the Fc-hole domain, or vice versa. This BsAb can retarget T cells to tumor cells. It is designed for the research of Acute myelogenous leukemia (AML); Chronic myelogenous leukemia (CML); Plasmacytoid leukemia therapy. |
) Donkey IgG (Control, non-immune, isotype control) |
|
20028-1 |
Alpha Diagnostics |
1 mg |
EUR 164 |
-control Control/blocking peptide) Rat neurofascin (Nfasc)-control Control/blocking peptide |
|
AB-23249-CP |
Alpha Diagnostics |
100ug |
EUR 164 |
 (Isotype control)) Rat IgG-Biotin conjugate (isotype control) (Isotype control) |
|
20005-B |
Alpha Diagnostics |
100 ug |
EUR 164 |
 (Isotype control)) Rat IgG-FITC conjugate (isotype control) (Isotype control) |
|
20005-F |
Alpha Diagnostics |
100 ug |
EUR 164 |
 (Isotype control)) Rat IgG-HRP conjugate (isotype control) (Isotype control) |
|
20005-HP |
Alpha Diagnostics |
100 ug |
EUR 164 |
 (Isotype control)) Rat IgG-PE conjugate (isotype control) (Isotype control) |
|
20005-PE |
Alpha Diagnostics |
25 tests |
EUR 202 |
 Hemoglobin A1c control |
|
35R-AH001 |
Fitzgerald |
1 ml |
EUR 256 |
|
Description: Hemoglobin A1c control |
 Goat IgG control |
|
31R-AG001 |
Fitzgerald |
1 mg |
EUR 127 |
|
Description: Goat Immunoglobulins Goat IgG control |
 Rabbit IgG Control |
|
31R-AR001 |
Fitzgerald |
500 ug |
EUR 133 |
|
Description: Purified Normal Rabbit IgG |
 Mouse IgG Control |
|
10R-I169A |
Fitzgerald |
250 ug |
EUR 127 |
|
Description: Mouse Immunoglobulins Mouse IgG Control |
 FMK Negative Control |
|
1122-100 |
Biovision |
|
EUR 175 |
|
FMK Negative Control |
|
1122-20C |
Biovision |
|
EUR 175 |
 Kemptide Negative Control |
|
5-01422 |
CHI Scientific |
4 x 5mg |
Ask for price |
 Compstatin control peptide |
|
B5478-1 |
ApexBio |
1 mg |
EUR 373 |
 Rabbit Isotype Control |
|
abx200646-100ug |
Abbexa |
100 ug |
EUR 328 |
- Shipped within 2-3 weeks.
|
 Rabbit Control IgG |
|
AC005 |
Abclonal |
100 ul |
EUR 133 |
 Mouse Control IgG |
|
AC011 |
Abclonal |
100 ul |
EUR 133 |
 Rat Control IgG |
|
AC034 |
Abclonal |
100 ul |
EUR 133 |
 IgG control Antibody |
|
abx234182-100ug |
Abbexa |
100 ug |
EUR 481 |
- Shipped within 5-12 working days.
|
 siRNA Negative Control |
|
20-abx941273 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
 TRAF6 Control Peptide |
|
H-7606.0001 |
Bachem |
1.0mg |
EUR 506 |
|
Description: Sum Formula: C139H232N34O42; CAS# [852690-80-3] net |
 CHO Control Antigen |
|
F063 |
Cygnus Technologies |
50 ul |
EUR 219 |
- Product category: Quality control/standard for molecular biology applications
|
|
Description: CHO Control Antigen by Cygnus Technologies is available in Europe via Gentaur. |
 SF9 Control Antigen |
|
F127 |
Cygnus Technologies |
50 ul |
EUR 240 |
- Product category: Quality control/standard for molecular biology applications
|
|
Description: SF9 Control Antigen by Cygnus Technologies is available in Europe via Gentaur. |
 S.cerevisiae Control Antigen |
|
F132 |
Cygnus Technologies |
50 ul |
EUR 219 |
- Product category: Quality control/standard for molecular biology applications
|
|
Description: S.cerevisiae Control Antigen by Cygnus Technologies is available in Europe via Gentaur. |
 L.lactis Control Antigen |
|
F497 |
Cygnus Technologies |
50 ul |
EUR 257 |
- Product category: Quality control/standard for molecular biology applications
|
|
Description: L.lactis Control Antigen by Cygnus Technologies is available in Europe via Gentaur. |
 PER.C6 Control Antigen |
|
F536 |
Cygnus Technologies |
70 ul |
EUR 334 |
- Product category: Quality control/standard for molecular biology applications
|
|
Description: PER.C6 Control Antigen by Cygnus Technologies is available in Europe via Gentaur. |
 Goat IgG Control |
|
GT15900 |
Neuromics |
1 mg |
EUR 166 |
|
Rabbit Isotype Control |
|
IMN-001 |
ImmunoStep |
100 µg |
EUR 199.5 |
 Mouse IgG1 Control |
|
ICIGG1A-50 |
ImmunoStep |
50 µg |
EUR 323 |
|
Mouse IgG1 Control |
|
ICIGG1AC750-50 |
ImmunoStep |
50 µg |
EUR 713 |
|
Mouse IgG1 Control |
|
ICIGG1CFB-100 |
ImmunoStep |
100 µg |
EUR 323 |
|
Mouse IgG1 Control |
|
ICIGG1F-100 |
ImmunoStep |
100 µg |
EUR 199.5 |
|
Mouse IgG1 Control |
|
ICIGG1PE-50 |
ImmunoStep |
50 µg |
EUR 323 |
|
Mouse IgG1 Control |
|
ICIGG1PP-100 |
ImmunoStep |
100 µg |
EUR 323 |
|
Mouse IgG1 Control |
|
ICIGG1PP5.5-100 |
ImmunoStep |
100 µg |
EUR 323 |
|
Mouse IgG1 Control |
|
ICIGG1PU-100 |
ImmunoStep |
100 µg |
EUR 199.5 |
 Mouse IgG2a Control |
|
ICIGG2AA-50 |
ImmunoStep |
50 µg |
EUR 323 |
|
Mouse IgG2a Control |
|
ICIGG2AB-100 |
ImmunoStep |
100 µg |
EUR 199.5 |
|
Mouse IgG2a Control |
|
ICIGG2ACFB-100 |
ImmunoStep |
100 µg |
EUR 323 |
|
Mouse IgG2a Control |
|
ICIGG2AF-100 |
ImmunoStep |
100 µg |
EUR 199.5 |
|
Mouse IgG2a Control |
|
ICIGG2APE-50 |
ImmunoStep |
50 µg |
EUR 323 |
|
Mouse IgG2a Control |
|
ICIGG2APP-100 |
ImmunoStep |
100 µg |
EUR 323 |
|
Mouse IgG2a Control |
|
ICIGG2APP5.5-100 |
ImmunoStep |
100 µg |
EUR 323 |
|
Mouse IgG2a Control |
|
ICIGG2APU-100 |
ImmunoStep |
100 µg |
EUR 199.5 |
 Mouse IgG2b Control |
|
ICIGG2BA-50 |
ImmunoStep |
50 µg |
EUR 323 |
|
Mouse IgG2b Control |
|
ICIGG2BCFB-100 |
ImmunoStep |
100 µg |
EUR 323 |
|
Mouse IgG2b Control |
|
ICIGG2BF-100 |
ImmunoStep |
100 µg |
EUR 199.5 |
|
Mouse IgG2b Control |
|
ICIGG2BPE-50 |
ImmunoStep |
50 µg |
EUR 323 |
|
Mouse IgG2b Control |
|
ICIGG2BPP-100 |
ImmunoStep |
100 µg |
EUR 323 |
|
Mouse IgG2b Control |
|
ICIGG2BPP5.5-100 |
ImmunoStep |
100 µg |
EUR 323 |
|
Mouse IgG2b Control |
|
ICIGG2BPU-100 |
ImmunoStep |
100 µg |
EUR 199.5 |
 Mouse IgG3 Control |
|
ICIGG3A-50 |
ImmunoStep |
100 µg |
EUR 648 |
|
Mouse IgG3 Control |
|
ICIGG3CFB-100 |
ImmunoStep |
100 µg |
EUR 388 |
|
Mouse IgG3 Control |
|
ICIGG3F-100 |
ImmunoStep |
100 µg |
EUR 323 |
|
Mouse IgG3 Control |
|
ICIGG3PE-50 |
ImmunoStep |
50 µg |
EUR 518 |
|
Mouse IgG3 Control |
|
ICIGG3PU-100 |
ImmunoStep |
100 µg |
EUR 323 |
 Mouse IgM Control |
|
ICIGMF-100 |
ImmunoStep |
100 µg |
EUR 199.5 |
|
Mouse IgM Control |
|
ICIGMPU-100 |
ImmunoStep |
100 µg |
EUR 199.5 |
 GFP Lentivirus Control |
|
LTV-300 |
Cell Biolabs |
1 vial |
EUR 566 |
|
Description: HIV-1 Lentivirus |
 RFP Lentivirus Control |
|
LTV-301 |
Cell Biolabs |
1 vial |
EUR 566 |
|
Description: HIV-1 Lentivirus |
 Control Magnetic Beads |
|
M1302-1 |
Biovision |
|
EUR 98 |
Due to the lack of vascular distribution and the sluggish metabolism, cartilage tissue can’t restore itself, which stays an enormous problem for cartilage regeneration. Tissue engineering utilizing stem cells seems to be a promising technique for cartilage restore. Tissue engineers demonstrated that mechanical stimulation can improve the high quality of engineered cartilage, making it extra much like pure cartilage in construction and performance. In this evaluate, we summarize current research on the position of mechanical stimuli in chondrogenesis, specializing in the purposes of extrinsic mechanical loading and the research on mechanical properties of biomaterials in cartilage tissue engineering. This evaluate will present contemporary insights into the potential use of mechanical stimuli for scientific use.
 Anti-p53 scFv IgG)
Recombinant (E.Coli) Anti-p53 scFv IgG 
pHrdSV40- scFv- GCN4- sfGFP- VP64- GB1- NLS 
pMD18- Control 
pMD19- Control 
Human IgG1 Control 
IgG control antibody